US-based Iambic Therapeutics and Japanese pharmaceutical giant Takeda Pharmaceutical Co. (TSE: 4502) announced a multi-year technology and discovery collaboration to design and develop new small-molecule medicines. The partnership will leverage Iambic’s AI-driven discovery platform to accelerate Takeda’s pipeline in high-priority therapeutic areas.
Details regarding the specific biological targets or the exact number of drug programs were not disclosed. Under the terms of the agreement, Iambic will receive upfront payments, research cost coverage, and technology access fees. The deal includes success-based development and commercial milestone payments that could exceed USD 1.7 billion, in addition to tiered royalties on net sales of any products resulting from the collaboration.
The collaboration establishes a rapid development model aimed at compressing traditional drug discovery timelines—potentially reducing the path to clinical trials from six years to less than two. Iambic will utilize its “Design-Make-Test-Analyze” cycle, integrating its NeuralPLexer and Enchant AI models with its automated wet lab capabilities. Takeda will gain specific access to the NeuralPLexer model to predict protein-ligand complexes, while both companies work to advance a select set of small-molecule programs initially focused on oncology and gastrointestinal and inflammatory diseases.